Mantle Cell Lymphoma

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the pace of progress in mantle cell lymphoma (MCL).

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses a 10-year single-center experience with TP53 status in mantle cell lymphoma (MCL).

Ezzat Elhassadi, MD, highlights research being done to address the unmet need of patients with p53-mutant mantle cell lymphoma and the challenges faced in the current treatment paradigm.

Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma.

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses data supporting the use of R-BAC (rituximab [Rituxan], cytarabine, and bendamustine) in mantle cell lymphoma (MCL).

Ezzat Elhassadi, MD, consultant hematologist, Haematology Services, University Hospital Waterford, discusses the outlook of patients with p53-mutated mantle cell lymphoma.

Reem Karmali, MD, MS, shares early data with ibrutinib maintenance therapy and highlights recent advances and challenges in the treatment of patients with mantle cell lymphoma.

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses an ongoing study in the frontline treatment of mantle cell lymphoma.

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the use of novel agents in patients with relapsed/refractory mantle cell lymphoma (MCL).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses challenges in treating patients with relapsed/refractory mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the preliminary results of a study which examined ibrutinib (Imbruvica) maintenance following induction in treatment-naïve patients with mantle cell lymphoma (MCL).

Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses ongoing work in mantle cell lymphoma.

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses targets under evaluation in mantle cell lymphoma.

Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.

Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses the watch-and-wait approach in mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging treatment strategies in mantle cell lymphoma.

Ann S. LaCasce, MD, MMSc, highlights recent progress made in MCL, exciting approaches under investigation, and provides insight into where future research should focus.

Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation (OXPHOS) and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib (Imbruvica) in mantle cell lymphoma.

Timothy Fenske, MD, MS, associate professor, Medical College of Wisconsin, discusses the future of daratumumab (Darzalex) in mantle cell lymphoma (MCL).

Timothy Fenske, MD, MS, discusses promising ongoing research in mantle cell lymphoma that will look to further advanced the evolving paradigm.

Clinical outcomes were found to be consistent among transplant-eligible patients with mantle cell lymphoma, irrespective of the chemoimmunotherapy induction regimen that was administered.

Bijal D. Shah, MD, oncologist/hematologist, Moffitt Cancer Center, discusses ongoing trials in the field of mantle cell lymphoma (MCL).

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses the future of mantle cell lymphoma treatment.

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses his recommendations for oncologists treating patients with mantle cell lymphoma (MCL) who are progressing on ibrutinib (Imbruvica).

Bijal D. Shah, MD, associate member, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses challenges with developing mantle cell lymphoma clinical trials.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment considerations in mantle cell lymphoma.

Although biological criteria carry prognostic value in mantle cell lymphoma, initial observation based solely on clinical criteria was found to be an effective management strategy that did not compromise patient outcomes.

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses key advances made in the mantle cell lymphoma (MCL) paradigm.

Ann S. LaCasce, MD, MMSc, highlights the therapeutic progress in the treatment of patients with mantle cell lymphoma , key remaining challenges, and where future research is headed.

Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses overcoming resistance to BTK inhibitors in the treatment of mantle cell lymphoma.